Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. So, what is mRNA? Messenger RNA (mRNA) already exists in your body. It carries a “message” - instructions that direct your cells what to do.

Moderna, Inc. (/ m ə ˈ d ɜːr n ə / mə-DUR-nə) [4] is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines.

We’re making biotech history. Since 2010, we have worked to build the industry's leading mRNA technology platform. Learn more about Moderna’s history.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases,...

2025年1月13日 · Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone.

Join us as we deliver the greatest possible impact to people through mRNA medicines. We are on a journey to becoming a real-time AI company, where we embed AI into every aspect of our organization. We know that successful AI implementation means putting our people at the center.

Deliver the greatest possible impact to people through mRNA medicines. Overview of Moderna news, events & presentations, latest quarterly results, and Moderna's pipeline development programs.

The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced …

2024年3月26日 · It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the decline of its Covid business.

CAMBRIDGE, MA / January 17, 2025 / Moderna, Inc. (NASDAQ: MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA ...